DaVita Inc. $DVA Stock Sold by Candriam S.C.A.

Candriam S.C.A. trimmed its holdings in DaVita Inc. (NYSE:DVA) by 14.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,885 shares of the company’s stock after selling 8,378 shares during the period. Candriam S.C.A.’s holdings in DaVita were worth $8,582,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Value Investment Professionals LLC grew its position in DaVita by 2.0% during the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock worth $556,000 after buying an additional 50 shares in the last quarter. Kesler Norman & Wride LLC raised its holdings in DaVita by 0.8% in the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after acquiring an additional 55 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in DaVita by 1.9% in the 3rd quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company’s stock valued at $560,000 after acquiring an additional 60 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in DaVita by 4.1% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock valued at $426,000 after acquiring an additional 76 shares in the last quarter. Finally, CoreCap Advisors LLC lifted its position in shares of DaVita by 161.7% during the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after acquiring an additional 97 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Price Performance

NYSE DVA opened at $185.51 on Tuesday. The business has a fifty day moving average price of $182.61 and a two-hundred day moving average price of $179.01. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The stock has a market capitalization of $11.67 billion, a PE ratio of 13.66, a PEG ratio of 0.49 and a beta of 0.87.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.57 by $0.25. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The firm had revenue of $3.58 billion for the quarter, compared to the consensus estimate of $3.52 billion. During the same quarter last year, the business posted $2.51 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. As a group, sell-side analysts expect that DaVita Inc. will post 14.66 earnings per share for the current year.

Wall Street Analyst Weigh In

DVA has been the topic of several analyst reports. Truist Financial reduced their target price on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Oppenheimer set a $220.00 price target on DaVita in a research note on Friday, August 7th. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. TD Cowen upped their price objective on shares of DaVita from $220.00 to $228.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Finally, Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, DaVita currently has a consensus rating of “Moderate Buy” and a consensus price target of $235.86.

DaVita Profile

DaVita Inc is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure.

The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets.

Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.